Operating cash flow was negative $2.9M in 2026Q3 and free cash flow remained negative in most quarters, with a -0.27 OCF-to-net-income ratio indicating reported profit did not translate into cash generation.
DataMEDS AI, Inc. (MEDS) cash flow statement — 3-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 |
|---|
| Cash from Operations | -15.5M | -10.86M | -1.22M | -349.14K |
| Operating CF Margin % | - | -46.51% | -6.76% | - |
| Operating CF Growth % | -484.83% | -786.13% | -250.86% | - |
| Net Income | -43.37M | -101.27M | -6.86M | -2.9M |
| Depreciation & Amortization | 5.07M | 3.21M | 1.11M | 0 |
| Stock-Based Compensation | 4.96M | 54.79M | 1.08M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 17.31M | 23.93M | 93.38K | 0 |
| Working Capital Changes | 575.07K | 8.48M | 3.34M | 2.55M |
| Change in Receivables | -1.54M | 799.77K | -40.08K | 0 |
| Change in Inventory | 124.8K | 1.89M | -72.36K | 0 |
| Change in Payables | 1.63M | 2.2M | -882.32K | 1.03M |
| Cash from Investing | 20.58K | -881.53K | 469.07K | 0 |
| Capital Expenditures | -255.38K | -881.53K | -377.29K | 0 |
| CapEx % of Revenue | 3.33% | 3.78% | 2.08% | - |
| Acquisitions | 0 | 0 | 931.37K | 0 |
| Investments | - | - | - | - |
| Other Investing | 275.96K | 0 | -85.01K | 0 |
| Cash from Financing | 11.73M | 10.75M | 1.78M | 350.5K |
| Debt Issued (Net) | 11.32M | -2.11M | 620.7K | 350K |
| Equity Issued (Net) | -326.69K | 12.86M | 10K | 500 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | -327.69K | 0 | 0 | 0 |
| Other Financing | 732.7K | 0 | 1.15M | 0 |
| Net Change in Cash | -3.75M | -985.76K | 1.03M | 1.36K |
| Free Cash Flow | -15.76M | -11.74M | -1.6M | -349.14K |
| FCF Margin % | -205.22% | -50.29% | -8.84% | - |
| FCF Growth % | -114.88% | -632.49% | -358.93% | - |
| FCF per Share | -3.98 | -8.27 | -1.54 | -0.39 |
| FCF Conversion (FCF/Net Income) | 0.36x | 0.11x | 0.18x | 0.12x |
| Interest Paid | -1.48M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying MEDS stock.
DataMEDS AI, Inc. (MEDS) generated $-10.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
DataMEDS AI, Inc. (MEDS) reported negative free cash flow of $11.7M in 2025, indicating capital requirements exceeded cash from operations.
DataMEDS AI, Inc. (MEDS) spent $0.9M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Metrics are mathematically derived from official filings.
Net Income Disconnected From Operating Cash
Based on reported figures, DataMEDS AI posted positive net income of $10.6M in 2026Q3 while operating cash flow was negative $2.9M, an OCF-to-net-income ratio of -0.27 that signals the reported profit did not convert into cash.
The gap between net income and operating cash flow is the central issue in this dataset, since the company reports profit in one quarter while consuming cash operationally. Across most quarters the OCF/NI ratio is low or negative, which suggests earnings are being driven by non-cash items or accruals rather than collected revenue. Investors should monitor whether the 2026Q3 profit reflects a one-time or non-cash gain, as it warrants further investigation before the earnings can be treated as durable.
Free Cash Flow Remains Persistently Negative
According to the reported statements, free cash flow was negative in every one of the ten quarters except 2024Q3, reaching -$6.5M in 2025Q4 and -$3.6M in 2026Q1, with FCF margins swinging from roughly -176% to +15%.
The consistent negative free cash flow indicates the business has not yet reached a level of operating scale that funds its own activity. Only the 2024Q3 quarter showed positive FCF of $820.5K, which appears to be an isolated period rather than an emerging trend. The recent quarters show FCF burn persisting at a multi-million dollar run rate, which may indicate continued reliance on external funding, although the data provided does not disclose financing sources.
Minimal Capital Intensity Limits Investment Read
Based on EDBL-style reported figures, CapEx runs between roughly 0.5% and 17% of revenue, with the 2026Q3 quarter showing a small positive investing value against otherwise modest outflows.
Capital expenditure is small in absolute terms and modest relative to revenue, so the business does not appear to be capital intensive. The drivers of cash burn therefore lie in operating costs rather than fixed-asset investment. Because D&A is also modest, the depreciation base offers little signal about asset replacement needs.
Working Capital Swings Mask Underlying Burn
As reported in financial statements, working capital changes ranged from a $4.8M inflow in 2025Q3 to a $2.1M outflow in 2026Q3, indicating that timing of receivables and payables has materially affected quarterly cash results.
Large swings in working capital suggest that quarterly operating cash flow is sensitive to collection and payment timing rather than steady operating performance. The 2025Q3 inflow of $4.8M appears to have temporarily offset operating losses, which means the underlying burn may be larger than headline quarterly figures imply. Investors should monitor whether these inflows reverse, as reversals could further pressure cash position.
Cumulative Earnings Versus Cash Reality
Based on reported figures, cumulative net income across the ten quarters is negative, while cumulative operating cash flow is also negative, with stock-based compensation of $27.8M and $25.7M in two quarters inflating the gap between accounting and cash results.
Both cumulative net income and cumulative operating cash flow are negative, so the company has not generated cash from operations over the period despite occasional profitable quarters. Large non-cash stock-based compensation charges in 2025Q1 and 2025Q3 appear to account for much of the difference between reported losses and cash burn. This suggests the cash economics are weaker than the accounting results alone would indicate, which warrants further investigation into the sustainability of the cost base.
Stock Compensation Obscures True Cash Burn
Based on reported figures, stock-based compensation of $27.8M in 2025Q1 and $25.7M in 2025Q3 may be masking the operating cash cost base, since non-cash charges of this scale can make reported losses look smaller than the cash the business consumes.
Stock-based compensation is excluded from operating cash flow, so the cash burn figures shown here already reflect that add-back, yet the equity dilution it implies is not captured in the cash line. Investors should monitor how much of the operating cost base is paid in shares rather than cash, since this affects both per-share value and the company's need for future external funding. The data provided does not disclose share count changes, so the dilution impact warrants further investigation.